Continued treatment with dupilumab (LIBERTY AD OLE) provides clinical benefits in most adults with moderate-to-severe atopic dermatitis not achieving optimal response to short-term treatment

Joo Young Roh

[PE10-7] Continued treatment with dupilumab (LIBERTY AD OLE) provides clinical benefits in most adults with moderate-to-severe atopic dermatitis not achieving optimal response to short-term treatment

Joo Young Roh¹, Young Lip Park², Chun Wook Park³, Zhen Chen⁴, Arima Kazuhiko⁵, Oh EunSil⁶, Brad Shumel⁴, Ana B Rossi⁷ (1.Gachon University, Gil Medical Center, Republic of Korea, 2.Soonchunhyang University, College of Medicine, Republic of Korea, 3.Hallym University, College of Medicine, Republic of Korea, 4.Regeneron Pharmaceuticals, Inc., USA, 5.Sanofi K.K., Japan, 6.Sanofi-aventis, Republic of Korea, 7.Sanofi Genzyme, USA)

パスワードは、参加登録をいただいた皆様にメールにてご案内させていただいております。なお、第69回学術大会抄録号（69巻6・7合併号）の「参加者へのお知らせ」にも掲載しております。

講演情報

[PE10] Poster Session 10
Atopic dermatitis 2

[PE10-7] Continued treatment with dupilumab (LIBERTY AD OLE) provides clinical benefits in most adults with moderate-to-severe atopic dermatitis not achieving optimal response to short-term treatment

パスワード

講演情報

[PE10] Poster Session 10Atopic dermatitis 2

[PE10-7] Continued treatment with dupilumab (LIBERTY AD OLE) provides clinical benefits in most adults with moderate-to-severe atopic dermatitis not achieving optimal response to short-term treatment

パスワード

[PE10] Poster Session 10
Atopic dermatitis 2